Zepbound: The Game-Changing Weight Loss Solution
Learn about the trial results of Zepbound, a new weight loss medication that has shown significant success in helping patients lose weight.
Latest right now for #obesity
WHO Endorses GLP-1 Drugs for Obesity: Global Guidelines for Long-Term Care
WHO endorses GLP-1 therapies for obesity, emphasizing long-term use with lifestyle interventions.
Zepbound Price Cut: $499/Month Self-Pay Vials Amid Access Push
Eli Lilly trims Zepbound vial prices to $499/month for self-pay patients, signaling broader obesity drug affordability amid industry and political pushes.
Decrease in Heart Attack Deaths in US
Learn about the recent study showing a significant decrease in heart attack deaths in American adults over the past five decades.
Pfizer's Monthly GLP-1 Obesity Injection Shows Competitive Promise
Pfizer's PF-08653944 shows promising monthly dosing with notable weight loss in the VESPER-3 trial and a competitive edge over weekly injections.
America's Deadliest Heart Conditions: Rising Risks and Prevention
Explores America's deadliest heart diseases, rising risk factors, and prevention strategies to reverse mortality trends.
Pfizer Wins $10B Metsera Acquisition Expands Obesity Treatment Pipeline
Pfizer secures a $10B deal to acquire Metsera, boosting obesity therapies and signaling strategic growth in biotech.
Eli Lilly's Oral GLP-1 Treatment for Obesity on Track for Global Regulatory Submissions
Learn about Eli Lilly's successful Phase 3 trial for orforglipron as a treatment for obesity and its potential impact on the pharmaceutical company and healthcare industry.
